Please assess the completion status of the following clinical trial:

Trial Title: Left Ventricular Functional Changes of Uncontrolled Diabetes by Dapagliflozin Treatment Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female affected by type 2 diabetes mellitus (T2D) for at least 6 months.~* Age ≥ 20 and ≤ 80 years.~* HbA1c levels 7.1%\~9.0% .~* On stable (at least 3 months) antidiabetic therapy with SGLT2 inhibitors naive.~* On stable (at least 3 months) cardio-active therapies (e.g. anti-hypertensive drugs, diuretics or drugs for hyperlipidemia).~* Preserved kidney function as defined by estimated glomerular filtration rate(eGFR)\> 60 mL/min/1.73m2.~* Preserved left ventricular function defined as EF ≥ 50% by echocardiographic screening.~Exclusion Criteria:~Subjects should not enter the study if any of the following exclusion criteria are fulfilled:~* Involvement in the planning and/or conduct of the study (applies to both Investigator staff and/or staff at the study site).~* Previous enrolment or randomisation in the present study.~* Participation in another clinical study with an investigational product during the last 3 months.~The exclusion criteria that follow are for example only; include, exclude, modify or add other criteria as appropriate.~* Refuse or inability to give informed consent.~* Patients unlikely to comply with the protocol or unable to understand the nature and possible consequences of the study.~* Employees of the investigator or study centre (i.e. principal investigator, sub-investigator, study coordinators, other study staff, employees, or contractors of each), with direct involvement in the proposed study or other studies under the direction of that investigator and/or study centre, as well as family members of the employees or the investigator.~* Pregnancy or active breast feeding.~* History of hospitalization for heart failure.~* History of stage C or D heart failure.~* History of myocardial infarction.~* History of cardiac dysrhythmia.~* Patients with a known hypersensitivity to Dapagliflozin or any of the excipients of the product.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Dapagliflozin add-on group (Type: ACTIVE_COMPARATOR): T2D subjects aged 20-80 years, presenting with HbA1C 7.1-9.0%, preserved kidney function (defined as estimated glomerular filtration rate (eGFR) \> 60 mL/min/1.73 m2), preserved LV function (defined as EF ≥ 50% by echocardiographic screening in the initial 2-week run-in period), and those treated with oral anti-diabetic drugs (except SGLT2i) and/or insulin therapy at least 3 months prior to the study were randomised to Dapagliflozin (10 mg/qd) add-on group.
- Standard of care (SOC) group (Type: ACTIVE_COMPARATOR): T2D subjects aged 20-80 years, presenting with HbA1C 7.1-9.0%, preserved kidney function (defined as estimated glomerular filtration rate (eGFR) \> 60 mL/min/1.73 m2), preserved LV function (defined as EF ≥ 50% by echocardiographic screening in the initial 2-week run-in period), and those treated with oral anti-diabetic drugs (except SGLT2i) and/or insulin therapy at least 3 months prior to the study were randomised to SOC treatment group.

Based on this trial design, predict the completion outcome and termination type (if applicable).